Evercore Wealth Management’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-886,031
| Closed | -$19.2M | – | 983 |
|
|
2017
Q2 | $19.2M | Sell |
886,031
-154,180
| -15% | -$2.8M | 0.74% | 41 |
|
|
2017
Q1 | $14.6M | Sell |
1,040,211
-12,230
| -1% | -$200K | 0.57% | 46 |
|
|
2016
Q4 | $19.7M | Sell |
1,052,441
-107,787
| -9% | -$1.83M | 0.82% | 42 |
|
|
2016
Q3 | $19.2M | Hold |
1,160,228
| – | – | 0.79% | 45 |
|
|
2016
Q2 | $15.6M | Buy |
1,160,228
+87,787
| +8% | +$1.28M | 0.69% | 45 |
|
|
2016
Q1 | $16.4M | Hold |
1,072,441
| – | – | 0.72% | 45 |
|
|
2015
Q4 | $21.3M | Sell |
1,072,441
-161,439
| -13% | -$3.07M | 0.99% | 36 |
|
|
2015
Q3 | $21.5M | Hold |
1,233,880
| – | – | 1.03% | 37 |
|
|
2015
Q2 | $24.9M | Sell |
1,233,880
-68,400
| -5% | -$1.32M | 1.13% | 34 |
|
|
2015
Q1 | $22.9M | Hold |
1,302,280
| – | – | 1.05% | 32 |
|
|
2014
Q4 | $21.2M | Sell |
1,302,280
-5,000
| -0.4% | -$91.8K | 1.06% | 36 |
|
|
2014
Q3 | $28.9M | Sell |
1,307,280
-24,200
| -2% | -$496K | 1.45% | 19 |
|
|
2014
Q2 | $26.8M | Hold |
1,331,480
| – | – | 1.38% | 20 |
|
|
2014
Q1 | $24.8M | Sell |
1,331,480
-31,000
| -2% | -$427K | 1.39% | 18 |
|
|
2013
Q4 | $13.7M | Sell |
1,362,480
-13,500
| -1% | -$163K | 0.75% | 49 |
|
|
2013
Q3 | $17.7M | Sell |
1,375,980
-19,000
| -1% | -$234K | 1.02% | 27 |
|
|
2013
Q2 | $16.6M | Buy |
+1,394,980
| New | +$15.1M | 0.94% | 30 |
|
Other funds holding AMRI
Evercore Wealth Management's AMRI Position: Q3 2017 in Review
Evercore Wealth Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 886,031 shares — an estimated $19.2M sold.
Evercore Wealth Management first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $28.9M in Q3 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Evercore Wealth Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Evercore Wealth Management sold 886,031 Albany Molecular Research Inc shares in Q3 2017, an estimated $19.2M.
- Evercore Wealth Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Evercore Wealth Management's Albany Molecular Research Inc position peaked at $28.9M in Q3 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Evercore Wealth Management's 13F filing for Q3 2017, filed 13 Nov 2017.